.svg){kind=small}
Dec-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Remedi has shown notable performance trends across different categories and states over the final months of 2025. In Illinois, the brand has made significant strides in the Concentrates category, improving its rank from 24th in September to 17th by December. This upward trajectory indicates a strengthening market presence, backed by a substantial increase in sales from October to November. Meanwhile, in the Tincture & Sublingual category within the same state, Remedi has maintained a consistently strong position, holding steady at 3rd place for most of the months, which reflects their solid footing in this category.
Conversely, in Massachusetts, Remedi's performance in the Concentrates category has faced more challenges. The brand did not rank within the top 30 in September, but eventually improved to 28th place by December. This movement suggests potential growth opportunities in the Massachusetts market, despite the initial lower ranking. The fluctuations in rankings highlight the competitive landscape and the brand's ongoing efforts to capture market share in this state. These insights reveal the varying degrees of success Remedi experiences across different regions and product categories, offering a glimpse into their strategic market positioning.
Competitive Landscape
In the Illinois concentrates market, Remedi has demonstrated a notable upward trajectory in its ranking over the latter months of 2025, moving from 24th in September to 17th by December. This improvement is particularly significant when compared to competitors such as Dabstract, which saw a decline from 16th to 21st, and Legacy Cannabis (IL), which fluctuated but ultimately improved slightly from 18th to 18th. Meanwhile, FloraCal Farms and UpNorth Humboldt maintained relatively stable positions, with FloraCal Farms climbing from 19th to 15th and UpNorth Humboldt experiencing a slight drop from 14th to 16th. This competitive landscape highlights Remedi's strategic gains in market presence, likely driven by a significant sales boost in November, positioning it as a rising contender in the concentrates category.
Notable Products
In December 2025, Remedi's top-performing product was the Indica Relief RSO Syringe (0.5g) in the Concentrates category, maintaining its number one rank from previous months with impressive sales of 1940 units. The Indica Rest RSO Dropper (0.5g) also held steady at the second position, indicating consistent consumer demand. The Indica Rest RSO Syringe (0.5g) remained third, though its sales saw a decline compared to November. Notably, the Lost Sailor x Chem Dawg RSO Syringe (1g) debuted in the rankings, securing the fourth spot. Meanwhile, the CBD/THC 1:5 Rest Tincture (20mg CBD, 100mg THC, 30ml) climbed back to fifth place after a dip in November, demonstrating a rebound in sales.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
